June 29, 2018 - Analysis of data from a clinical trial conducted at Vanderbilt suggests that deep brain stimulation (DBS) administered to patients with very early-stage Parkinson’s disease slowed the progression of rest tremor. The study, published June 29 in Neurology, is significant because it is the first evidence of a treatment that may possibly delay the progression of one of the cardinal features of Parkinson’s disease.

A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.

Despite benefiting from dramatic improvements in movement after deep brain stimulation surgery, patients with Parkinson’s disease can be inadequately served when physicians and researchers focus only on its motor manifestations, says a Vanderbilt neurosurgeon.

A long-term Vanderbilt University Medical Center study of deep brain stimulation (DBS) in early-stage Parkinson’s disease has received approval from the Food and Drug Administration (FDA) to continue in a pivotal, phase III, large-scale safety and efficacy trial.

Deep brain stimulation used to treat Parkinson’s disease may impair some aspects of language processing, a recent study suggests.

Neuronal activity in a deep brain region increases as Parkinson’s disease advances, a new study suggests.